Two Sigma Investments’s iTeos Therapeutics ITOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-122,697
Closed -$1.25M 3345
2024
Q3
$1.25M Buy
122,697
+35,077
+40% +$535K ﹤0.01% 1984
2024
Q2
$1.3M Buy
87,620
+7,568
+9% +$108K ﹤0.01% 1841
2024
Q1
$1.09M Buy
80,052
+52,835
+194% +$576K ﹤0.01% 1904
2023
Q4
$298K Buy
+27,217
New +$270K ﹤0.01% 2700
2022
Q3
Sell
-25,600
Closed -$527K 2633
2022
Q2
$527K Sell
25,600
-199,008
-89% -$4.72M ﹤0.01% 1801
2022
Q1
$7.23M Buy
224,608
+17,225
+8% +$626K 0.02% 747
2021
Q4
$9.66M Buy
207,383
+39,613
+24% +$1.32M 0.02% 803
2021
Q3
$4.53M Buy
167,770
+66,646
+66% +$1.74M 0.01% 1302
2021
Q2
$2.59M Buy
+101,124
New +$2.41M 0.01% 1666

Other funds holding ITOS

Two Sigma Investments's ITOS Position: Q4 2024 in Review

Two Sigma Investments sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 122,697 shares — an estimated $1.25M sold.

Two Sigma Investments first reported a position in ITOS in Q2 2021 and held it in 9 quarters. The position peaked at $9.66M in Q4 2021. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Two Sigma Investments reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Investments sold 122,697 iTeos Therapeutics shares in Q4 2024, an estimated $1.25M.
  • Two Sigma Investments first reported a position in iTeos Therapeutics in Q2 2021 and held it in 9 quarters.
  • Two Sigma Investments's iTeos Therapeutics position peaked at $9.66M in Q4 2021.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Two Sigma Investments's 13F filing for Q4 2024, filed 14 Feb 2025.